Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20044128rdf:typepubmed:Citationlld:pubmed
pubmed-article:20044128lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C1519429lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0278689lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C1522690lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:20044128lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:20044128pubmed:issue3lld:pubmed
pubmed-article:20044128pubmed:dateCreated2010-2-15lld:pubmed
pubmed-article:20044128pubmed:abstractTextRandomized phase 3 trials have demonstrated the utility of a regimen of carboplatin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer, and have provided provocative data suggesting a substantially lower risk of carboplatin-associated hypersensitivity if PDL is delivered in combination with the platinum agent.lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:languageenglld:pubmed
pubmed-article:20044128pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:citationSubsetIMlld:pubmed
pubmed-article:20044128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20044128pubmed:statusMEDLINElld:pubmed
pubmed-article:20044128pubmed:monthMarlld:pubmed
pubmed-article:20044128pubmed:issn1095-6859lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:AlbertsDavid...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:MarkmanMaurie...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:LopezAna...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:RowlandKendri...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:AndersonGarne...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:WilczynskiSha...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:MoonJamesJlld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:MichelinDavid...lld:pubmed
pubmed-article:20044128pubmed:authorpubmed-author:LanzottiVicto...lld:pubmed
pubmed-article:20044128pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20044128pubmed:volume116lld:pubmed
pubmed-article:20044128pubmed:ownerNLMlld:pubmed
pubmed-article:20044128pubmed:authorsCompleteYlld:pubmed
pubmed-article:20044128pubmed:pagination323-5lld:pubmed
pubmed-article:20044128pubmed:dateRevised2011-7-25lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:meshHeadingpubmed-meshheading:20044128...lld:pubmed
pubmed-article:20044128pubmed:year2010lld:pubmed
pubmed-article:20044128pubmed:articleTitleSingle agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.lld:pubmed
pubmed-article:20044128pubmed:affiliationUniversity of Texas, M.D. Anderson Cancer Center, Unit 1435, Houston, TX 77030, USA. mmarkman@mdanderson.orglld:pubmed
pubmed-article:20044128pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20044128pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:20044128pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20044128pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:20044128pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
pubmed-article:20044128pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20044128lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20044128lld:pubmed